Research in the last decade has expressed considerable optimism about the clinical
potential of psychedelics for the treatment of mental disorders. This optimism is reflected in …

One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Objective: Ketamine has been redeveloped as a rapid-acting antidepressant for treatment-
resistant depression (TRD). There is a paucity of literature comparing subanesthetic …

Quantifying neural activity in natural conditions (ie conditions comparable to the standard
clinical patient experience) during the administration of psychedelics may further our …

Abstract Treatment-resistant depression (TRD) represents a severe clinical condition with
high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been …

Importance The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With
Treatment Resistant Depression (TRD)(ELEKT-D) trial demonstrated noninferiority of …

The growing interest in the rapid and sustained antidepressant effects of the dissociative
anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However …

Ketamine is an effective antidepressant, but there is substantial variability in patient
response and the precise mechanism of action is unclear. Neuroimaging can provide …

Concurrent with recent insights into the neuroprogressive nature of depression, ketamine
shows promise in interfering with several neuroprogressive factors, and has been suggested …

Chronic pain is commonly linked with diminished working memory. This study explores the
impact of the anesthetic (S)-ketamine on spatial working memory in a chronic constriction …